Enzalutamide Prior to Radium-223 Is Associated with Better Overall Survival in Metastatic Castration-Resistant Prostate Cancer Patients Compared to Abiraterone—A Retrospective Study

SIMPLE SUMMARY: Radium-223 is a bone-targeted radiopharmaceutical that has been shown to improve overall survival (OS) and reduce bone pain in patients with metastatic castration-resistant prostate cancer (mCRPC). In this study, we evaluated the efficacy and safety of radium-223 in patients with mCR...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Hao Xiang, Tsai, Li-Hsien, Chang, Chao-Hsiang, Wu, Hsi-Chin, Lin, Ching-Chan, Lin, Che-Hung, Yeh, Chin-Chung, Yang, Chi-Rei, Lien, Chi-Shun, Chang, Yi-Huei, Liang, Ji-An, Chen, Guan-Heng, Hsiao, Po-Jen, Hsieh, Po-Fan, Huang, Chi-Ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10340515/
https://www.ncbi.nlm.nih.gov/pubmed/37444626
http://dx.doi.org/10.3390/cancers15133516

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10340515/
https://www.ncbi.nlm.nih.gov/pubmed/37444626
http://dx.doi.org/10.3390/cancers15133516

Ejemplares similares